A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study

2019/10/22 by Roisin E. O’Cearbhaill, Wei Deng, Lee-may Chen +13
Immunology and Microbiology · Medicine · #Immunotherapy and Immune Responses #Ovarian cancer diagnosis and treatment #Reproductive System and Pregnancy

paper · doi:10.1016/j.ygyno.2019.09.015

Citations

• Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
• A Multiple Testing Procedure for Clinical Trials